Effects of Adoptive Immunotherapy on T Cell Subsets of Peripheral Blood in Non-small Cell Lung Cancer Patients
-
摘要: 目的 研究细胞因子诱导的杀伤（cytokine-induced killer，CIK）细胞治疗对非小细胞肺癌（non-small cell lung cancer，NSCLC）患者外周血T细胞亚群及一般情况的影响。方法 采集非小细胞肺癌患者外周血，常规方法体外扩增CIK细胞，分三次回输患者体内，流式细胞仪检测非小细胞肺癌患者治疗前与治疗3次后T细胞亚群的变化，分析其与健康对照组相比外周血T细胞亚群的差异，并观察CIK细胞治疗前后患者一般情况变化。结果 与对照组相比，NSCLC患者外周血中CD3+ T 细胞比例、CD3+CD4+T细胞比例、CD4+/CD8+ 比值显著下降（P<0.05），CD3+CD8+ T细胞比例显著升高（P<0.05）。CIK细胞治疗后与治疗前，CD3+ T 细胞比例、CD3+CD4+ T细胞比例、CD4+/CD8+ T细胞比值显著升高（P<0.05），CD3+CD8+ T细胞比例显著降低（P<0.05）。CIK细胞治疗后与对照组相比，CD3+ T 细胞比例、CD4+/CD8+T细胞比值显著下降（P<0.05）。CD3+CD4+ T细胞比例、CD3+CD8+ T细胞比例升高，但差异无统计学意义（P>0.05）。CIK细胞治疗前Tregs较对照组显著升高（P<0.05）。CIK细胞治疗后与治疗前相比，Tregs比例显著下降（P<0.05）。结论 CIK细胞输注治疗可以增强NSCLC患者的免疫功能，并改善患者的一般情况，提高生活质量，且未见明显不良反应。
-
关键词:
- 细胞因子诱导的杀伤细胞 /
- 非小细胞肺癌 /
- 免疫功能 /
- 调节性T细胞
Abstract: Objective To investigate the effect of cytokine-induced killer(CIK) cells therapy on T cell subsets in the peripheral blood and general condition of non-small cell lung cancer (NSCLC) patients. Methods Peripheral blood mononuclear cells (PBMCs) were collected from the peripheral blood of NSCLC patients. CIK cells were expanded by classical protocol, re-infused to the patients once a day for 3 consecutive days. Before and after 3 courses of CIK cells therapy, the changes of T cell subsets were assessed by flow cytometry, and the difference of T cell subsets between patients and healthy subjects were analyzed. General condition of NSCLC patients was observed before and after the therapy. Results Compared with the control group, the expression of CD3+T cells, CD3+CD4+T cells, CD4+/CD8+ T cells in the peripheral blood of NSCLC patients were significantly decreased (P<0.05), the expression of CD3+CD8+ T cells were significantly increased (P<0.05). After the CIK cells therapy, the expression of CD3+ T cells, CD3+CD4+ T cells, CD4+/CD8+ T cells were significantly increased (P<0.05); while the expression of CD3+CD8+ T cells were significantly decreased (P<0.05). Compared with the control group, the expression of CD3+ T cells and CD4+/CD8+ T cells were significantly decreased (P<0.05) after CIK cells therapy; the expression of CD3+CD4+ T cells and CD3+CD8+ T cells were increased (P>0.05). Tregs in NSCLC patients before CIK cells therapy were significantly increased compared with the control group (P<0.05), and Tregs in stage Ⅲ~Ⅳ patients were significantly higher than that in stage Ⅰ~ Ⅱ patients(P<0.05). After CIK cells therapy, Tregs in stage Ⅰ~ Ⅱ and stage Ⅲ~Ⅳ patients were significantly decreased compared with those before CIK cells therapy(P<0.05). After CIK cells therapy, Tregs in stage Ⅰ~ Ⅱ patients were significantly lower than that in the control group (P<0.05).Tregs in stage Ⅲ~Ⅳ patients were still higher than that in the control group(P>0.05). Conclusion CIK cells therapy could enhance the immunity, improve general condition and quality of life of NSCLC patients without obvious side effects. -
-
[1] Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion[J]. Science, 2011, 331(6024): 1565-70． [2] Feliciano J, Feigenberg S, Mehta M. Chemoradiation for definitive, preoperative, or postoperative therapy of locally advanced nonsmall cell lung cancer[J]. Cancer J, 2013, 19(3): 222-30. [3] Urbanska K, Lanitis E, Poussin M, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor[J]. Cancer Res, 2012, 72(7): 1844-52. [4] Andersen MH, Sørensen RB, Brimnes MK, et al. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients[J]. J Clin Invest, 2009, 119(8): 2245-56. [5] Liu L, Zhang W, Qi X, et al. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma[J]. Clin Cancer Res, 2012, 18(6): 1751-9. [6] Li R, Wang C, Liu L, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study[J]. Cancer Immunol Immunother, 2012, 61(11): 2125-33. [7] Shi M, Zhang B, Tang ZR, et al. Autologous cytokine-induced killer cell therapy in clinical trial phase Ι is safe in patients with primary hepatocellular carcinoma [J]. World J Gastroenterol, 20 04, 10(8):1146-51. [8] Shepherd FA, Douillard JY, Blumenschein GR Jr. Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome[J]. J Thorac Oncol, 2011, 6(10): 1763-73. [9] Broderick I, Yokota SJ, Reineke J, et al. Human CD4+ effector memory T cells persisting in the microenvironment of lung cancer xenografts are activated by local delivery of IL-12 to proliferate, produce IFN-gamma, and eradicate tumor cells[J]. J Immunol, 20 05, 174(2): 898-906. [10] Jin CG, Chen XQ, Li J, et al. Moderating effects and maintenance of lung cancer cellular immune functions by CIK cell therapy[J]. Asian Pac J Cancer Prev, 2013, 14(6): 3587-92. [11] Filaci G, Fenoglio D, Fravega M, et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers[J]. J Immunol, 2007, 179(7): 4323-34. [12] Najafian N, Chitnis T, Salama AD, et al. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model[J]. J Clin Invest, 2003, 112(7): 1037-48. [13] Yue Q, Zhang X, Ye HX, et al. The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma [J]. Neurooncol, 2014, 116(2): 251-9. [14] Wang LK, Kuang M, Hua YP, et al. Profile of regulatory T cells and interferon γ secretion in the tumor-draining lymph node from mouse Hepa1-6 cells[J]. J Surg Res, 2013, 183(2): 900-6. [15] Zou W. Regulatory T cells, tumour immunity and immunotherapy[J]. Nat Rev Immunol, 2006, 6(4): 295-307. [16] Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer[J]. Cancer Res, 2001, 61(12): 47 66-72. [17] Li H, Yu JP, Cao S, et al. CD4+CD25+ regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients[J]. J Clin Immunol, 2007, 27(3): 317-26. [18] Xu WL, Cai JH, Li SL, et al. Effect of interfering tumor microenvironment on homing and killilng activity of cytotoxic T lymphocytes[J]. Zhong Liu Fang Zhi Yan Jiu, 2014, 41(12): 12 86-91.[徐立伟, 蔡建辉, 李索林, 等. 干扰肿瘤微环境对细胞毒 性T淋巴细胞瘤体内归巢和杀伤活性的影响[J]. 肿瘤防治研究, 20 14, 41(12): 1286-91.]
计量
- 文章访问数: 1195
- HTML全文浏览量: 333
- PDF下载量: 378
下载:
